Mark E. Bunnage
EVP, Chief Scientific Officer at Vertex Pharmaceuticals Inc / Ma (VRTX) since February 2026
Mark E. Bunnage has filed 6 insider reports with the SEC since February 2026, as EVP and chief Scientific Officer at Vertex Pharmaceuticals Inc / Ma (VRTX). In the last 12 months Mark E. Bunnage sold $3M of stock on the open market. In the latest filing, on May 19, 2026, Mark E. Bunnage sold 33 shares of Vertex Pharmaceuticals Inc / Ma (VRTX) for $15K at an average of $453.45.
- Filings
- 6
- Companies
- 1
- Bought on market
- None
- Sold on market
- $3M
Companies where Mark E. Bunnage is an insider
| Company | Role | Shares held | Bought | Sold | Avg buy | Price now | Last filing |
|---|---|---|---|---|---|---|---|
| EVP, Chief Scientific Officersince February 2026 | 7,284 | $3M | $536.45 | May 19, 2026 |
Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.
Every filing
- May 15, 2026-$15KVRTXEVP, Chief Scientific Officer Bunnage Mark E. sold $14,964 worth of shares (33 units at $453.45) as part of a pre-agreed trading plan, decreasing direct ownership by 0.45% to 7,284 unitsForm 4Open-market sale10b5-1 plan
- Feb 25, 2026-$302KVRTXEVP, Chief Scientific Officer Bunnage Mark E. covered exercise/tax liability with 582 shares and sold $301,537 worth of shares (620 units at $486.35), decreasing direct ownership by 14% to 7,284 unitsForm 4Shares withheld for taxes or exercise priceOpen-market sale10b5-1 plan
- Feb 18, 2026-$1.75MVRTXEVP, Chief Scientific Officer Bunnage Mark E. was granted 2,584 shares, covered exercise/tax liability with 1,110 shares and sold $1,752,704 worth of shares (3,619 units at $484.31), decreasing direct ownership by 20% to 8,486 unitsForm 4Grant or awardShares withheld for taxes or exercise priceOpen-market sale10b5-1 plan
- Feb 13, 2026VRTXEVP, Chief Scientific Officer Bunnage Mark E. covered exercise/tax liability with 2,283 shares, decreasing direct ownership by 18% to 10,631 unitsForm 4Shares withheld for taxes or exercise price
- Feb 11, 2026-$931KVRTXEVP, Chief Scientific Officer Bunnage Mark E. sold $930,529 worth of shares (2,021 units at $460.43) and covered exercise/tax liability with 1,127 shares, decreasing direct ownership by 20% to 12,914 unitsForm 4Shares withheld for taxes or exercise priceOpen-market sale10b5-1 plan
- Feb 1, 2026VRTXNew insider Bunnage Mark E. claimed ownership of 16,062 sharesForm 3New insider
Compare Mark E. Bunnage with
- Mark E. Bunnage vs Charles F Wagner Jr1 shared
- Mark E. Bunnage vs Reshma Kewalramani1 shared
- Mark E. Bunnage vs Jasper van Grunsven1 shared
- Mark E. Bunnage vs Kristen Ambrose1 shared
- Mark E. Bunnage vs Bruce I Sachs1 shared
- Mark E. Bunnage vs Ourania Tatsis1 shared
Other insiders at the same companies
- Nancy ThornberryVRTX
- Sangeeta N. BhatiaVRTX
- Charles F Wagner JrVRTX
- Reshma KewalramaniVRTX
- Jasper van GrunsvenVRTX
- Kristen AmbroseVRTX
- Bruce I SachsVRTX
- Ourania TatsisVRTX
- Amit SachdevVRTX
- Alan M GarberVRTX
- Duncan McKechnieVRTX
- Joy LiuVRTX
- Carmen BozicVRTX
- Suketu UpadhyayVRTX
- Jennifer SchneiderVRTX
- Diana MckenzieVRTX
Questions about Mark E. Bunnage
- What is Mark E. Bunnage's role at Vertex Pharmaceuticals Inc / Ma?
- Mark E. Bunnage reports to the SEC as EVP and chief Scientific Officer at Vertex Pharmaceuticals Inc / Ma (VRTX), according to the latest filing on May 19, 2026.
- How many shares does Mark E. Bunnage own?
- After the latest filing that states it, Mark E. Bunnage directly owned 7,284 shares of Vertex Pharmaceuticals Inc / Ma (VRTX). Shares held through trusts, funds or family members are reported separately and are not counted here.
- Has Mark E. Bunnage bought or sold stock recently?
- The most recent open-market sale was on May 15, 2026: sold 33 shares of Vertex Pharmaceuticals Inc / Ma (VRTX) for $15K at an average of $453.45.
- How do I get alerts when Mark E. Bunnage files?
- Follow Mark E. Bunnage on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.
From SEC Forms 3, 4, 5 and 144 filed by Mark E. Bunnage (SEC CIK 0002100735). Totals count each trade once, skipping amendments whose original is on file, from Feb 3, 2026 on. View on SEC EDGAR